1,731
Views
8
CrossRef citations to date
0
Altmetric
Review

Pathogenesis guided therapeutic management of COVID-19: an immunological perspective

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 54-71 | Received 21 Jun 2020, Accepted 17 Oct 2020, Published online: 28 Oct 2020
 

Abstract

Lack of standardized therapeutic approaches is arguably the significant contributor to the high burden of mortality observed in the ongoing pandemic of the Coronavirus disease, 2019 (COVID-19). Evidence is accumulating on SARS-CoV-2 specific immune cell dysregulation and consequent tissue injury in COVID-19. Currently, no definite drugs or vaccines are available against the disease; however initial results of the ongoing clinical trials have raised some hope. In this article, taking insights from the emerging empirical evidence about host-virus interactions, we deliberate upon plausible pathogenic mechanisms and suitable therapeutic approaches for COVID-19.

Disclosure statement

All the authors declare “No Conflict of Interest.”

Author contributions

A.K. wrote the first draft. P.P., P.S.S., V.P., M.A.F., C.K., R.K.N., M.K., and K.K. revised the draft. P.P. and A.K. prepared tables and figures.

Additional information

Funding

There was no dedicated funding for this project.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.